The company depends on a limited number of suppliers, including sole suppliers, for laboratory instruments, materials, and certain technology components. Aptar is the sole supplier of the intranasal Unit Dose Spray (UDS) product, which serves as the delivery system for the company's Intranasal Epinephrine powder and Intranasal Naloxone powder. If Aptar is unable to supply UDS in the required quantities or fails to meet supply obligations, the company may encounter challenges in securing alternative suppliers on acceptable terms. Transitioning to a different UDS manufacturer would necessitate verification of quality standards, regulatory compliance, and potentially conducting bridging studies, potentially delaying product development. External factors such as natural disasters, epidemics, acts of war, or political instability at third-party supplier facilities could disrupt manufacturing capacity or quality. Failure to maintain existing supplier agreements or establish new ones could adversely affect the company's commercialization efforts and financial condition.
Nasus Pharma Ltd's Comment on Supply Chain
The company depends on a limited number of suppliers, including sole suppliers, for laboratory instruments, materials, and certain technology components. Aptar is the sole supplier of the intranasal Unit Dose Spray (UDS) product, which serves as the delivery system for the company's Intranasal Epinephrine powder and Intranasal Naloxone powder. If Aptar is unable to supply UDS in the required quantities or fails to meet supply obligations, the company may encounter challenges in securing alternative suppliers on acceptable terms. Transitioning to a different UDS manufacturer would necessitate verification of quality standards, regulatory compliance, and potentially conducting bridging studies, potentially delaying product development. External factors such as natural disasters, epidemics, acts of war, or political instability at third-party supplier facilities could disrupt manufacturing capacity or quality. Failure to maintain existing supplier agreements or establish new ones could adversely affect the company's commercialization efforts and financial condition.
Sources:
Nasus Pharma Ltd 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Nasus Pharma Ltd ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
